PHE study shows vaccines effective in reducing severe coronavirus (COVID-19)

PHE study shows vaccines effective in reducing severe coronavirus (COVID-19)

Public Health England (PHE) has submitted a pre-print of a real-world study, in which it contends that the Pfizer and Oxford-AstraZeneca vaccines prove highly effective in reducing coronavirus (COVID-19) infections among people aged over 70 and over. According to the study, since January 2021 protection against symptomatic coronavirus four weeks after the first dose was given ranged between 57–61% for a single dose of Pfizer and 60–73% for the Oxford-AstraZeneca vaccine.

The data of the study also showed that for people over 80 a single dose of either the Pfizer or Oxford-AstraZeneca vaccine was more than 80% effective at preventing hospitalisation from three or four weeks after the jab took place. In addition, for the Pfizer vaccine, there was evidence suggesting that it led to an 83% reduction in deaths from coronavirus.

The study:

•  compared the rate of vaccination in symptomatic people aged over 70 years of age who tested positive for coronavirus, compared to those who tested negative

• compared the rate of hospitalisation in confirmed coronavirus cases in people aged over 80 who were vaccinated more than 14 days before testing positive, compared to unvaccinated cases

• compared the rate of deaths in confirmed coronavirus cases in people aged over 80 who were vaccinated with Pfizer vaccine more than 14 days before testing positive, compared to unvaccinated cases

Source: New data show vaccines reduce severe COVID-19 in older adults

Related Articles:
Latest Articles: